

EASD

EUROPEAN ASSOCIATION FOR THE STUDY OF DIABETES

ASSOCIATION EUROPEENNE POUR L'ETUDE DU DIABETE · EUROPÄISCHE GESELLSCHAFT FÜR DIABETOLOGIE

Rheindorfer Weg 3 · D-40591 Düsseldorf · Germany · Tel: +49-211-7 58 46 90 · Fax: +49-211-75 84 69 29

E-mail: easd@uni-duesseldorf.de · Homepage: <http://www.easd.org>

EASD

News Section

12/2002

7th Scientific Meeting of the EASD Hypertension in Diabetes (HID) Study Group

Hotel Continental, Tirrenia, Pisa, Italy, 26–27 April 2002



Dr Andrea Natali, the Local Organiser, welcomed established and new members of the Hypertension in Diabetes (HID) group to the small resort of Tirrenia on the Tuscan coast near his home town of Pisa. The first scientific session, entitled “Endothelium” – in keeping with the group’s strong and developing interest in vascular biology – reflected an increasingly sophisticated understanding of the physiological role of insulin in modulating vascular tone. Consistent data were presented from the groups in Amsterdam (Stehouwer, Eringa et al) and Glasgow (Petrie, Cleland et al) demonstrating that insulin can act as both a vasodilator and vasoconstrictor depending on the experimental model and conditions.

These data were nicely placed in context in an Invited Lecture from Coen Stehouwer (Amsterdam) on “Endothelium and microvasculature in insulin resistant states.” He included novel data on potentiation of skin microvascular responses to endothelium-depen-

dent agonists during hyperinsulinaemia, including what he described as the “first direct evidence” of capillary recruitment in man (nailfold capillaries) by insulin. The debate regarding the importance or otherwise of impaired insulin action on the vasculature in causing resistance to insulin-mediated glucose uptake (last rehearsed at the group’s scientific meeting in Budapest 1998 by Natali and Petrie), was updated in a highly informed discussion in which the potential role for heterogeneity within conventional disease categories was acknowledged.

A second more clinical scientific session, entitled “Ambulatory Blood Pressure” concentrated on aspects of blood pressure (BP) measurement, including an intriguing cross-over study from Professor Ravid’s group on the influence of nocturnal waking on night time blood pressure values. Other presentations from Poland and Hungary concentrated on the role of autonomic dysfunction, measured using power spectral

analysis, on parameters of blood pressure control. After lunch, in a third scientific session entitled “Epidemiology/ nephrology”, chaired by John Yudkin (UK), investigators reported novel data on the methodology of assessment of “salt sensitivity” (Jelic, Yugoslavia) and of its presence in the offspring of people with Type 2 diabetes (Strojek, Poland). Further presentations concentrated on the impact of new guidelines on the apparent prevalence of hypertension in people with diabetes (Stern, Israel), and the difficulties of assessing the impact of ethnicity on complications when using data from community diabetes registers (Baskar, UK).

An invited lecture from Antonio Colantuoni (Italy) entitled “Insulin In Microvascular Function” reported some apparently tyrosine kinase *independent* effects of insulin on vascular responses in a classical hamster cheek pouch preparation. Delegates then heard complimentary presentations from Israel (Levy, Rachmani et al) and Italy/London (Toschi, Natali, Baldweg, Yudkin, Ferrannini et al) on the effects of rosiglitazone on the vasculature in rodents and man. The consistent message was that the thiazolidinedione PPAR γ agonists appear to have potentially beneficial effects on surrogate markers of vascular function which are not dependent on glucose-lowering. Investigations of the mechanisms involved (direct or indirect?) will now represent a major research theme, while the results of outcome trials are awaited.

In the final session, Peter Nilsson (Sweden) shared with the group his deliberations on the design of a study about to commence in Malmo assessing the effect of rosiglitazone on carotid intima-media thickness. In the last invited lecture, Professor Antonio Salvetti (Italy) discussed “How difficult and how good it is to lower blood pressure in diabetic patients?” This was a comprehensive and well-balanced up-to-the-minute review of the ever-growing canon of randomised control trials in this area, including the recently-published LIFE study. He cautioned against the widespread assumption that ACE inhibitors and angiotensin II receptor blockers should be preferred over other drug classes in all patients with diabetes, concluding that the presence of suggestive data does not constitute conclusive evidence – particularly with respect to diabetes prevention and nephroprotection. UK delegates noted that the Italian version of the phrase “one swallow does not make a summer” involves the *primavera* (spring) season, reflecting regrettable climatic differences! Finally, Professor Salvetti offered a critique of the increasing tendency of non-evidence based guidelines to promote systolic blood pressure targets of <130mmHg, and highlighted the importance of some lesser known important ongoing studies including Prevention of Events with Angiotensin-Converting Enzyme Inhibition (PEACE), European trial on Reduction of cardiac events with Perindopril in sta-

ble Coronary Artery Disease (EUROPA), and Valsartan Antihypertensive Long term Use Evaluation (VALUE). Subsequent discussion seemed to reach a consensus that formal comparisons of different combinations of therapy should be preferred in the design of future trials, rather than the usual emphasis on individual agents.

The scientific content was complemented by the beautiful seaside venue and a guided tour of the Piazza de Miracoli – where the famously Leaning Tower, the Cathedral and the Baptistry are situated. Delegates were treated to a demonstration of how the multiply-arched structure of the baptistry allows a singer to produce multiple harmonies without the aid of technology. They were also reminded of Galileo’s excommunication from the church for heresy, and of his death in poverty and blindness. The gala dinner was held in “Bruno’s” – a famous restaurant close to the Leaning Tower. Delegates were surprised when they realised that they were to be served all eleven courses listed on the menu! Those who had professed concern about the world pandemic of obesity and insulin resistance during the scientific sessions seemed to have forsaken their anxieties in the hope that the typical regional red wines (selected by Dr Natali) would offer cardioprotection.

At the business meeting, Professor Peter Sawicki (Germany) was elected as President, replacing Professor Ravid (Israel) who has served over the previous three years. In addition, Professor Grzeczak (Poland) replaced Dr Krzysztof Strojek (Poland) as Vice-President. Dr Peter Nilsson, a founding member of the group, who has since been active in the European Society of Hypertension “Working Group on Diabetes,” was once again elected to the Executive Committee. The practical expectation is that HID will liaise more closely with this nascent group, with the possibility of a joint meeting to be held in 2004.

Further information on the Hypertension in Diabetes (HID) study group is available to interested individuals by writing or emailing the address below. Attendance at annual meetings, is open to all (membership of EASD is not compulsory) who submit, or have previously submitted, an abstract chosen for presentation during the annual meeting.

John Petrie
Secretary, EASD Hypertension in Diabetes (HID)
Study Group
Division of Cardiovascular and Medical Sciences
3rd Floor, Queen Elizabeth Building
Royal Infirmary
Glasgow, G31 2ER
UK
Email: jrp1s@clinmed.gla.ac.uk

EASD Health Economics and Diabetes Care Delivery Study Group

In Europe, as in the rest of the world, the prevalence of diabetes is increasing and, as a result, the health and economic burden on the individual and the community is growing. At the same time, advances in health technology and clinical evidence create higher expectations of health and well-being from increasingly well-informed consumers.

Diabetes care has a multidisciplinary and multifaceted nature touching upon many players across the Health System and offering a focus to bring together different strands of activities whose impact on care need to be assessed using the accepted scientific methods available to provide robust evidence.

Research, as production of scientific knowledge, is closely interlinked with user perspectives, and the spectrum of activities actually covered by the study groups of the EASD shows a gap in research areas that have a considerable impact on clinical daily practice: disease management, health economics, health services research, health care delivery and quality of care improvement.

The aim of the working group will be to promote research on these topics in order to find ways of implementing effective and efficacious health care in diabetes. Bringing together specialists in the above mentioned fields who are active in research will create an environment to further development in the cooperative efforts to improve diabetes health care.

The name of the group will be: **EASD Health Economics and Diabetes Care Delivery Study Group**. The Study Group will have a restricted number of members; this number will not exceed 30. An

annual scientific meeting will cover original scientific studies on the subjects covered by the aim of the group.

The project of this new Study Group was presented to the General Assembly during the Annual Meeting of the EASD in Budapest in September 2002. The Study Group will ask for final approval of the Council and General Assembly of EASD on the occasion of the 18th IDF Congress to be held in Paris, France in August 2003. The Study Group will prepare the first scientific meeting during the IDF Congress in Paris in 2003 by calling for results of scientific work in the above mentioned fields of research.

We would like to invite you, as a person active in at least one of the fields of the future **EASD Health Economics and Diabetes Care Delivery Study Group**, to become a member. We expect you to be an active member of the group which will encourage scientific work to improve the delivery of effective and efficacious diabetes care.

Dr. Fred Storms
Honorary Secretary of the Steering Committee
to create the EASD Health Economics
and Diabetes Care Delivery Study Group

Mesos Diabetes Centrum Bilthoven
Prof. Bronkhorstlaan 12
NL-3723 MB Bilthoven
The Netherlands
Email: stormdcb@wxs.nl

JOSEPH HOET RESEARCH AWARD – 2003

The DPSG (Diabetic Pregnancy Study Group, EASD) announces the First Joseph Hoet Research Award (First JHRA) to be given on the occasion of the Annual Meeting of the Study Group (Sant Salvador, El Vendrell, Spain), 29 August – 2 September 2003. The 2003 DPSG Meeting would be organized in conjunction with the Second Annual Meeting of the IADPSG (International Association of Diabetic Pregnancy Study Group), immediately after the 2003 IDF (International Diabetes Federation) Congress in Paris.

The award will consist of a commemorative plaque and a diploma-certificate, travel expenses and Euro 7.000 for the awardee, with the support of HemoCue AB. The call for nominations is open, on a competitive basis, for excellence of research in the field of Diabetes and Pregnancy, under the following conditions:

1. The candidate must be younger than 45 years on 1 January of the year of the award.
2. There is no restriction concerning the nationality of candidates.
3. The JHRA will be given in relation to research of excellence in the field of Diabetes and Pregnancy (Basic or Clinical) manifested by publications with important contribution to the advancement of knowledge in the field.
4. **Before 15 April in the year of the Award**, the Chairman of the DPSG should receive all documents for nomination, which include 6 copies of the candidate's Curriculum Vitae with complete bibliography, 6 copies of each of the most relevant publications (not more than 15) and 6 copies of a statement by the candidate, explaining the manner in

which the research and the publications have contributed to the advancement of knowledge concerning the area of Diabetes and Pregnancy. Such a statement should not exceed 1.000 words. Additional letters of support of relevant authorities in the field of Diabetes and Pregnancy may be also enclosed.

5. The jury to decide on the award will be formed by the four active members of the DPSG Board plus another member, chosen by the official representatives of HemoCue AB among ordinary/honorary DPSG members or, if not European, an ordinary/honorary member of the International Association of Diabetic and Pregnancy Study Groups (IADPSG). Only in exceptional cases, if the jury cannot make a final choice between 2 final candidates, with almost identical evaluation, the DPSG Chair's vote will be decisive.

The recipient of the prize is expected to give the Joseph Hoet Lecture, describing his/her most important scientific achievements during the annual DPSG meeting, and is also expected to write a respective review article for publication in *Diabetologia* (if this is accepted by the Editorial office of the journal).

6. Applications should be addressed to the Chairman of DPSG:

Prof. Moshe Hod

Director, Perinatal Division
and WHO Collaborating Center for Perinatal Care
Rabin Medical Center – Beilinson Campus
Tel – Aviv University
IL-49100 Petah – Tiqua
Israel
E-mail: mhod@clalit.org.il

Council Membership Nominations 2004 – 2007

Dear Member,

The EASD invites nominations for council membership for the period September 2004 – September 2007. The nominations will be considered by the members of the Executive Committee and Council of the EASD.

The nominee should be a paid-up member of the Association. Nominations must include a letter of re-

commendation, signed by three EASD members and should be sent to the

EASD Secretariat
Rheindorfer Weg 3
D-40591 Düsseldorf
Germany

to arrive not later than **1 March 2003.**

Minkowski Prize 2003

Members of the EASD are invited to submit nominations for the 2003 Minkowski Prize, which since 1966 has been generously sponsored by Aventis Inc. The prize consists of a Certificate and Euro 20,000 (Euro twenty thousand) plus travel expenses. The candidate must be less than 40 years of age on 1 January 2003.

The prize will be given in relation to research, which has been carried out by a person normally resident in Europe. It is awarded for distinction manifested by publications, which contribute to the advancement of knowledge concerning diabetes mellitus.

Nominations or re-nominations should be in the form of **six copies** of the candidate's curriculum vitae, including a complete bibliography, **six copies** each of the most relevant publications (not more than ten), and **six copies** of a statement in English by the proposer(s) explaining the manner in which the candidate's published contributions have aided knowledge

concerning diabetes mellitus. Such a statement should not exceed 1,000 words. Additional letters of support will be disregarded.

Nominations or re-nominations should be sent to the
EASD Secretariat
Rheindorfer Weg 3
D-40591 Düsseldorf
Germany

to arrive **not later than 15 February 2003**.

The recipient of the Prize is expected to give the 38th Minkowski Lecture describing his/her most important scientific achievements during the 18th IDF Congress, which will be held in Paris, France, 24-29 August 2003, and is expected to write a respective review article for publication in *Diabetologia*.

Claude Bernard Lecturer 2004

Members of the EASD are invited to submit nominations for the 2004 Claude Bernard Lecturer. The EASD is very grateful to the Paul Neumann Foundation (Aventis, France) for their continuous support of this award. The Lecture will be delivered during the 40th EASD Annual Meeting to be held in Munich, Germany, 5-9 September 2004.

There are no restrictions regarding the age of the candidate who may come from any part of the world. The aim of the Lectureship is to recognise an individual's innovative leadership and outstanding contributions to the advancement of knowledge in the field of diabetes mellitus and related metabolic diseases. The Claude Bernard Medal is presented to the chosen Lecturer, whose travel expenses to the Annual Meeting are also paid.

Nominations or re-nominations should be in the form of a letter of recommendation of not more than 1000 words and should include the curriculum vitae of the nominee and a list of not more than ten relevant publications.

Six copies of each should be sent to the
EASD Secretariat
Rheindorfer Weg 3
D-40591 Düsseldorf
Germany

to arrive **not later than 15 April 2003**.

In addition, one copy of a full bibliography of the candidate should be provided.

Castelli Pedroli Prize 2003

Members of the EASD are invited to submit nominations for the 2003 Castelli Pedroli Prize. The prize consists of an award of Euro 8,000 (Euro eight thousand), presented by the family of the late Maria Carla Castelli Pedroli.

The prize is awarded for outstanding contributions in the field of the histopathology, pathogenesis, prevention and treatment of the complications of diabetes mellitus, which has been carried out in Europe by a member of the EASD normally resident in Europe. The recipient should have a distinguished track record of research in the field. Publications in internationally recognised scientific journals over the last 5 years should demonstrate continuing activity, originality and excellence in the field.

Nominations or re-nominations may be submitted by any member of the EASD, and should comprise of **six copies** of each of the following:

- a) Curriculum vitae of the candidate
- b) Letter of recommendation
- c) Re-prints of the eight most important publications emphasising recent contributions.

Nominations or re-nominations should be sent to the

EASD Secretariat
Rheindorfer Weg 3
D-40591 Düsseldorf
Germany

to arrive **not later than 15 February 2003**.

The recipient of the prize will be required to deliver a lecture named in honour of Camillo Golgi during the 18th IDF Congress, to be held in Paris, France, 24-29 August 2003.

EASD / GlaxoSmithKline Burden of Diabetes Research Fellowship

The EASD / GlaxoSmithKline Fellowship is open to members of the EASD who are under the age of 36 years in the year of the award. This fellowship will be awarded for the best proposal for a research project that will further define the full extent of the burden of Type 2 (non-insulin-dependent) diabetes and its complications. This burden encompasses the problems associated with pathogenesis and clinical management of the disease and its complications as well as their psychosocial, epidemiological and economic impact. It is envisaged that the fellowship will provide a salary and research materials in the amount of £ 30,000 (thirty thousand Pounds Sterling) for the successful candidate over 1 year (full time) or 2 years (part time). The money awarded will be paid into the account of the host institution.

The application should also include:

- a) Full name, address, date of birth and brief curriculum vitae of the applicant.
- b) Proof of current EASD Membership.
- c) List of publications by applicant as first or co-author
- d) Date and nature of appointment held by applicant, with brief résumé of work on which currently employed.

- e) A report providing full details of the project for which the fellowship is required. This should cover the aims, background, methodology and hoped-for results of the project.
- f) Letter of commitment from the host institution.

Application can be made to only one fellowship/award. For the EASD / GlaxoSmithKline Burden of Diabetes Research Fellowship, **six copies** of the application should be sent to the

EASD Secretariat
Rheindorfer Weg 3
D-40591 Düsseldorf
Germany

to arrive **not later than 1 March 2003**.

The EASD / GlaxoSmithKline Burden of Diabetes Research Fellowship will be announced annually by the President of EASD during the General Assembly of the Association.

Upon completion of the fellowship, the recipient is requested to submit a final report to the EASD of the study carried out.

The EASD / Amylin – Paul Langerhans Research Fellowship for Research on the Physiology and Pathophysiology of the Beta-Cell

The objective of the EASD / Amylin – Paul Langerhans Research Fellowship is to encourage research in the field of physiology and pathophysiology of the beta-cell. The award honours the memory of Paul Langerhans who discovered the islet cells of the pancreas.

Applicants should have demonstrated their ability in the field of diabetes research.

One fellowship will be awarded annually in the sum of US\$40,000 (forty thousand US dollars); the money awarded will be paid into the account of the host institution.

The following regulations shall apply: Application may be made by any paid-up member of the EASD under the age of 40 years on 1 January in the year of the award. The application shall consist of:

- a) Full name, address, date of birth and brief curriculum vitae of the applicant.
- b) Proof of current EASD Membership
- c) List of publications by applicant as first or co-author.
- d) Date and nature of appointment held by applicant, with brief résumé of work on which currently employed.

e) A report (not more than 2-3 pages) providing full details of the project for which the fellowship is required. This should cover the aims, background, methodology and hoped-for results of the project.

f) Letter of commitment from the host institution.

Applications can be sent for only one fellowship/award. For the EASD / Amylin – Paul Langerhans Research Fellowship, **five copies** of the application should be sent to the

EASD Secretariat
Rheindorfer Weg 3
D-40591 Düsseldorf
Germany

to arrive **not later than 15 February 2003**.

The EASD / Amylin – Paul Langerhans Research Fellowship will be announced annually by the President of EASD during the General Assembly of the Association.

EASD – ADA Fellowships

The European Association for the Study of Diabetes and the American Diabetes Association are pleased to announce the availability of research fellowships designed to bring European and American scientists into closer collaboration, fostering a synergy of efforts to improve the lives of people with diabetes around the world.

These fellowships, which are supported by the **EFSD – Lilly Research Fund**, are designed to encourage research into basic or clinical questions related to diabetes or its complications. Applications will be judged on the strength of the applicant's previous and current work, the feasibility and importance of the research plan, and the research environment in which the applicant will work. All fellows will be encouraged to present their work at the appropriate EASD or ADA Annual Meeting.

Two fellowships are available each year: one to support an investigator from Europe to study in the US, and one for a US fellow to study in Europe. An

award of US \$50,000 will be made to the host institution. The award amount should cover one year's salary of the awardee, and the remaining amount may be used for travel costs and for laboratory equipment or supplies. It is expected that eligible fellows will have completed their advanced degree (MD, PhD, or equivalent) within the previous 7 years. Complete application forms can be found on the Associations' web sites: www.easd.org and www.diabetes.org.

Purpose:

EASD-ADA Fellowships are designed to encourage research into basic or clinical questions related to diabetes or its complications and to foster closer links between the research communities in Europe and the United States.

Support:

The award will be made for the stipend support of a postdoctoral fellow in a given year, as well as labora-

tory supplies and travel costs. Two fellowships are available each year: one for a fellow from Europe studying in the US, and one for a US fellow studying in Europe. Awards of US\$50,000 will be made to the host institution. Of the award amount, US\$35,000 can be allotted for the salary support of the fellow, US\$5,000 for travel costs, and US\$10,000 for laboratory equipment or supplies.

Eligibility Requirements:

It is expected that eligible fellows will have completed their advanced degree (MD, PhD, or equivalent) within the previous 7 years. The fellow cannot be serving an internship or residency during the fellowship period. The fellow must devote at least 80% of time and effort to diabetes research during the fellowship. Applications will be judged on the strength of the applicant's previous work, the feasibility and importance of the research plan, and a demonstrated commitment to the field of diabetes research. At the conclusion of the fellowship, fellows will be encouraged to present their work at the EASD or ADA Annual Meetings.

An eligible candidate from Europe must be an EASD member and a citizen or permanent resident of a European country. An eligible candidate from the United States must be an ADA member and a US citizen or permanent resident. Eligible institutions in Europe or the United States must be recognized non-profit research institutions. Fellows will be offered complementary membership in their host Association (EASD or ADA) during the period of their fellowship.

Terms:

An award year commences on 1 July and ends on 30 June. Funds will be paid to the institution in US dollars in quarterly payments beginning 1 July. A progress report is required by 30 March following the award period.

Acknowledgement of support from the EASD and the ADA must be made when findings resulting from the fellowship are published or presented. The fellow must agree to inform the ADA and the EASD of his or her professional status, research support, and all publications for a period of five years following completion of the fellowship.

Review Criteria:

Particular attention will be given to:

- The quality and activity of the applicant's current research.
- The novelty, feasibility, and importance of the applicant's research plan.
- The research environment in which the applicant will work.

Submission:

Application must be made on the forms provided. Twelve copies of the application form plus the original must be submitted. Applications should be sent to the EASD or ADA office in the applicant's home region on or before 1 February. Successful applicants will be notified of the award by 11 April. The applicant may send an email to the appropriate office requesting a confirmation of the receipt of the application.

Applications from EASD members should be sent to:

EASD Secretariat
Rheindorfer Weg 3
D-40591 Düsseldorf
Germany
www.easd.org

Applications from the USA should be sent to:

American Diabetes Association
1701 North Beauregard Street
Alexandria, Virginia 22311
USA
Tel +1-703-5491500
Fax +1-703-5491715
www.diabetes.org/research
research@diabetes.org

Deadline for applications is 1 February 2003.

Successful applicants will be notified of the award by 1 April. Funding begins on 1 July 2003 and ends on 30 June 2004.

European Foundation for the Study of Diabetes

The Research Foundation of the European Association for the Study of Diabetes

Albert Renold Career Development Award of the European Foundation for the Study of Diabetes

Professor Albert Ernst Renold (1923-1988) was the founding Secretary of the European Association for the Study of Diabetes (EASD) from 1965-1970, and later served as President of EASD from 1974-1977. He was also President of the International Diabetes Federation from 1979-1982. He played a major role in advancing diabetes research both in Europe and throughout the world until his untimely death.

The Award:

To commemorate the considerable debt owed to Albert Renold for his inspirational leadership, and to help the most promising young investigators further their career in diabetes research by visiting another laboratory, the *European Foundation for the Study of Diabetes (EFSD)* has instituted the Albert Renold Career Development Award. This was the first award offered by the funding arm of the EASD and is the most prestigious European award for young investigators in the field of diabetes research.

This Award has been established to further the career in diabetes research of outstanding young investigators by allowing them to work in another (preferably foreign) laboratory to gain experience in new techniques or to carry out collaborative research. The initial award will be for one year. Candidates may apply for one additional year of funding (2 years total) on the understanding that this will be based on merit and subject to review by the Executive Committee of a scientific progress report and a justification for the additional year of funding.

The Candidate:

Candidates must be paid-up members of the EASD and have a PhD, MD or equivalent degree. Unless exceptional circumstances apply, the candidate must be under the age of 35 (PhD) or 40 years (MD or MD/PhD with clinical training) on 1 January in the year of the award. Preference will be given to individuals who have already demonstrated, through their publications in peer reviewed journals, their commitment to diabetes research and will typically be reserved for those who have not as yet secured a tenured Faculty position.

Nominations:

Candidates for this Award must be nominated by a senior scientist or physician (see below) and may not apply on their own behalf.

Budget:

The Albert Renold Career Development Award will provide up to Euro 60,000 per annum for salary (according to local salary scale). A research allowance of Euro 20,000 will be made available to the host laboratory to cover costs of supplies. In addition, travel expenses not to exceed Euro 3,000 will be provided for the candidate and his/her family.

This award will be offered by EFSD on an annual or bi-annual basis, subject to availability of funds.

The nomination shall consist of:

- a) Full name, address, date of birth and curriculum vitae of the candidate.
- b) Proof of current EASD membership.
- c) Complete list of publications of the candidate as first or co-author, with "peer reviewed articles" and "other articles" (reviews, book chapters etc.), listed separately. Abstracts will not be considered.
- d) Date and nature of present appointment held by candidate, with brief (one page) résumé of work on which currently employed (to be written by the candidate).
- e) Full details (max. 3 pages) of the project for which the Albert Renold Career Development Award is sought. This should be written by the candidate and should be in the form of a short protocol covering the aims, background, methodology, and hoped-for results. References are not included in the 3 page limit but should be limited to <30.
- f) Letter of nomination describing the qualities of the candidate and explaining how he/she will benefit from the proposed visit to the other laboratory and outlining any plans for his/her future career at the end of the award.
- g) Letter from the director of the laboratory to be visited confirming that the application has his/her approval and describing the means (laboratory and office space, equipment, supplies in addition to the Euro 20,000 research allowance etc.) to be placed at the candidate's disposal as well as how the director

and/or his/her colleagues will ensure that the candidate receives necessary training and encouragement to allow for successful completion of the project.

h) Confirmation of local salary for the candidate.

Nominations can be sent for a maximum of two fellowships/awards.

Eight copies of the nomination should be sent to the European Foundation for the Study of Diabetes
Rheindorfer Weg 3
D-40591 Düsseldorf
Germany

to arrive **not later than 15 February 2003**.

Election to the Albert Renold Career Development Award will be made by the Executive Committee of the EFSD. The Award will be available to the recipient from 1 July 2003. The successful candidate is required to send a written report to the EASD Secretariat within 3 months of completion of the Award.

The Albert Renold Career Development Award will be announced annually by the President of the EASD during the General Assembly of the Association.

EFSD / Eli Lilly Research Fellowship in Diabetes and Metabolism

The objective of the EFSD / Eli Lilly Research Fellowship is to encourage research in the field of diabetes and metabolism and to promote excellence in medical education. Applicants should have demonstrated their ability in the field of diabetes research.

One fellowship will be awarded annually in the sum of US\$35,000 (thirty-five thousand US dollars); the money awarded will be paid into the account of the host institution.

The following regulation shall apply:

Application may be made by any paid-up member of the EASD under the age of 40 years on 1 January in the year of the award. The application shall consist of:

- a) Full name, address, date of birth and brief curriculum vitae of the applicant.
- b) Proof of current EASD Membership.
- c) List of publications by applicant as first or co-author
- d) Date and nature of appointment held by applicant, with brief résumé of work on which currently employed

e) A report (not more than 2-3 pages) providing full details of the project for which the fellowship is required. This should cover the aims, background, methodology and hoped-for results of the project.

f) Letter of commitment from the host institution.

For the EFSD / Eli Lilly Research Fellowship in Diabetes and Metabolism, **six copies** of the application should be sent to the

European Foundation for the Study of Diabetes
Rheindorfer Weg 3
D-40591 Düsseldorf
Germany

to arrive **not later than 15 February 2003**.

The EFSD / Eli Lilly Fellowship will be announced annually by the President of EASD during the General Assembly of the Association. Upon completion of the fellowship, the recipient will be invited to present his/her research results at a scientific meeting held at Eli Lilly and Company.

EFSD / Eli Lilly Research Fellowship in Diabetes Microvascular Complications

The objective of the EFSD / Eli Lilly Research Fellowship is to encourage research in the field of diabetes Microvascular complications with particular emphasis on diabetic retinal disease and to promote excellence in medical education. Applicants should have demonstrated their ability in the field of diabetes research.

One fellowship will be awarded annually in the sum of US\$ 35,000 (thirty-five thousand US dollars); the money awarded will be paid into the account of the host institution.

The following regulations shall apply:

Application may be made by any paid-up member of the EASD under the age of 40 years on 1 January in the year of the award, who has a PhD, MD or equivalent degree. The application shall consist of:

- a) Full name, address, date of birth and brief curriculum vitae of the applicant
- b) Proof of current EASD Membership
- c) List of publications by applicant as first or co-author
- d) Date and nature of appointment held by applicant, with brief résumé of work on which currently employed

- e) An application (not more than 3 pages) providing full details of the project for which the fellowship is required. This should cover the aims, background, methodology and potential benefit to patients with diabetes
- f) Letter of commitment from the host institution

For the EFSD / Eli Lilly Fellowship in Diabetes Microvascular Complications, **five copies** of the application should be sent to the

European Foundation for the Study of Diabetes
Rheindorfer Weg 3
D-40591 Düsseldorf
Germany

to arrive **not later than 15 February 2003**.

The EFSD / Eli Lilly Fellowship will be announced annually by the President of the EASD during the General Assembly of the Association. Upon completion of the fellowship, the recipient will be invited to present his/her research results at a scientific meeting held at Eli Lilly and Company.

EFSD / MSD Travel Fellowships for Young Scientists

The *European Foundation for the Study of Diabetes (EFSD)* / MSD Travel Fellowships will enable young scientists to travel to and stay at other laboratories in order to learn different scientific techniques. The duration of the stay should not exceed 3 months. Eight Fellowships can be awarded in the year 2003. Each award will be for up to Euro 6,000.

The following regulations will apply:

Applications may be made by any paid-up member of the EASD under the age of 35 years (PhD) or 40 years (MD) on 1 January in the year of the award. The application should include:

- a) Full name, address, date of birth and brief curriculum vitae of the applicant
- b) Proof of current EASD Membership

- c) Statement of how the visit will benefit the applicant and his/her department (1 side A4 maximum)
- d) Date and nature of present appointment held by applicant
- e) Letter of recommendation by the Head of the Department
- f) Letter from the host institution describing the objectives of the stay
- g) Budget details

Three copies of the application should be sent to the

European Foundation for the Study of Diabetes
Rheindorfer Weg 3
D-40591 Düsseldorf
Germany

These Travel Fellowships are available throughout the whole year.

Announcements

Second International Course on Diabetes and Macrovascular Disease Lugano, Switzerland, 27–29 March 2003

Co-chairpersons: A. Chait (USA)
M.-R. Taskinen (Finland)

The home page for the Diabetes 2003 Course is located at: <http://www.lorenzinfoundation.org>

List of the Scientific Sessions:

- Diabetes Mellitus - a global problem
(Cockram C.S., Chait A., Kahn S.)
- Pathogenesis of vascular disease
(Despres J.-P., Yki-Järvinen H., Juhan-Vague I.)
- Risk factors for CVD in diabetes
(Fioretto P., Taskinen M.-R., Shimomura I.)
- Lessons from clinical trials
(Holman R.R., Berne C., Armitage J., Barter P.J.)
- Current tactics to attack
(Syväne M., Heine R.J., Paoletti R., Fruchart J.-C.)

For further information, please contact:

Scientific-Organizing Secretariat
Diabetes Course 2003
Fondazione Giovanni Lorenzini
I-20121 Milan
Italy
Tel: +39 2 29006267
Fax: +39 2 29007018
Email: info@lorenzinfoundation.org

6th Diabetic Neuropathy Satellite Symposium to the 18th International Diabetes Federation Congress in conjunction with the 13th Annual Meeting of the Diabetic Neuropathy Study Group of the EASD (NEURODIAB XIII)

Saint Malo, France, 30 August – 2 September 2003

Deadline for submission of abstracts: **1 March 2003.**

For registration please contact:

Agence EVIC
58, rue Trousseau
F-75011 Paris
France
Tel : +33-1-4923 0117
Fax : +33-1-4923 8019
E-mail: camillevoisin@evicenevents.com
Website: www.evicenevents.com

For abstract submission please contact:

Prof. Andrew Boulton
Chairman, Scientific Committee
Department of Medicine
Orange Zone Corridor
Manchester Royal Infirmary
Oxford Road
Manchester, M13 9WL
UK
Tel : +44 161 276 4452
Fax : +44 161 274 4740
E-mail: aroscoe@central.cmht.nwest.nhs.uk

For further information please contact:

Prof. Dan Ziegler
Chairman, Organising Committee
and NEURODIAB
German Diabetes Research Institute
at the Heinrich Heine University
Auf'm Hennekamp 65
D-40225 Düsseldorf
Germany
Tel: +49-211-33821
Fax: +49-211-3382277 or +49-211-3382603
E-mail: dan.ziegler@ddf.uni-duesseldorf.de
Website: www.neurodiab.org

4th International Symposium on the Diabetic Foot

Noordwijkerhout, The Netherlands, 22–24 May 2003

This quadrennial symposium is aimed at all health care workers, interested in the treatment and management of the Diabetic Foot. Detailed information can be found at:

www.diabeticfoot.nl

For further information, please contact:

Nicolette van Erven
Symposium Coordinator
Convenience Conference Management
P.O. Box 77
NL-3480 DB Harmelen
The Netherlands
Tel: +31 348 567667
Fax: +31 348 446057
E-mail: nve@convenience-cm.nl

8th Scientific Meeting of the EASD Hypertension in Diabetes (HID) Study Group (HID 2003)

Leiden, The Netherlands, 22–24 May 2003

Local organiser of this meeting is Professor Coen Stehouwer.

The abstract deadline is **10 January 2003**.

For further information, please contact:

John Petrie
Secretary, EASD Hypertension in Diabetes (HID) Study Group
E-mail: j.r.petrie@clinmed.gla.ac.uk

The 38th Meeting of the Scandinavian Society for the Study of Diabetes

Helsinki, Finland, 4–6 April 2003

Deadline for abstracts: **31 January 2003**.

Deadline for early registration: **1 March 2003**

Registration fee: Euro 50 for members and Euro 75 for non-members

Registration and information: www.diabetes.fi/sssd or e-mail: sssd@diabetes.fi

Programme (*Oral and poster presentations will be integrated with the sessions*):

Friday 04.04.2003:

9.00–17.00 Satellite symposium 'Islet development and stemcells in diabetes'

9.00–14.00 Meeting of diabetes nurses: Scandinavian approaches in patient education: *Birtha Hansen, Lillemor Fernström, Marit Graue, Outi Himanen*

17.00–19.00 Poster Exhibition
Satellite symposium with welcome reception

Saturday 05.04.2003

8.30–16.00
Insulin resistance in muscle and the heart:
Juleen Zierath, Pirjo Nuutila

Insulin resistance in liver and adipose tissue:
Hannele Yki-Järvinen, Peter Arner

Genetics of Type 2 diabetes and cardiovascular disease:
Anders Hamsten, Markku Laakso

8.30–16.00

Cell replacement therapy in diabetes: *Bernat Soria, Harry Heimberg, Eduard Montany, Christian Berne*

Pathogenesis of Type 1 diabetes: *Flemming Pociot, Olli Simell, Mikael Knip*

16.00 Novo Nordisk Foundation Lecture

Sunday 06.04.2003

9.00 Young Investigator Award

9.30 Pathophysiology of Type 2 diabetes:
Leif Groop, Ulf Smith

9.30 Genetics and pathophysiology of diabetic nephropathy: *Per-Henrik Groop, Allan Flyvbjerg*

11.30 Knud Lundbaek Award

Oral and poster presentations will be integrated with the sessions.

For further information, please contact:

www.diabetes.fi/sssd
sssd@diabetes.fi

or

Dr. Tiinamaija Tuomi
Helsinki University Central Hospital
PO Box 340
FIN-00029 HUS
Helsinki
Finland
Fax: +358-9-4717 5798
Tiinamaija.Tuomi@hus.fi

International Symposium on ‘Mechanisms of beta-cells death in Type 1 diabetes mellitus and following islet transplantation’

Brussels, Belgium, 21 February 2003

To commemorate the opening of the Juvenile Diabetes Research Foundation (JDRF) Center for Prevention of Beta-Cell Destruction in Europe, an international symposium will be organised on “Mechanisms of beta-cell death in type 1 diabetes mellitus and following islet transplantation”. The symposium will take place at the Medical Faculty, Université Libre de Bruxelles, Brussels, on Friday, 21.02.2003, from 13:00-19:00.

Registrations are free and will take place on a “first comes first” basis. The closing date for registration is 3 February 2003, and registered participants will receive additional information on location and the final programme.

For information and registration, please contact:

Decio L. Eizirik
Laboratoire de Médecine Expérimentale,
Université Libre de Bruxelles - CP 618,
Route de Lennik, 808,
B-1070 Bruxelles, Belgium
E-mail: deizirik@ulb.ac.be
Phone: +32-2-555 62 42
Fax: +32-2-555 62 39

13th European Meeting on Hypertension

Fiera Milano Congressi Center – Pavillon 17, Milan, Italy, 13–17 June 2003

Important dates

Deadline for submission of abstracts: 15 January 2003

Deadline for registration at the reduced fee: 31 March 2003

Deadline for hotel reservation: 15 April 2003

Credits

Attendance at this Meeting will provide credits for application as Hypertension Specialist or the European Society of Hypertension.

Internet

The second announcement is available on the internet at:

www.aimgroup.it/2003/esh

Organising Committee:

Chairman

Giuseppe Mancia

University of Milano-Bicocca

S. Gerardo Hospital

Dept of Clinical Medicine Prevention and Applied Biotechnologies

Via Donizetti, 106

I-20052 Monza - Milan

Italy

Tel: +39-039-2333357

Fax: +39-039-322274

E-mail: giuseppe.mancia@unimib.it

Organising Secretariat:

AISC & MGR - AIM Group

Rome Office:

Via A. Ristori, 38

I-00197 Rome

Italy

Tel: +39-06-809681

Fax: +39-06-80878491

E-mail: esh2003@aisc.it

Other Announcements

Paulescu Award

The Romanian Federation of Diabetes, Nutrition & Metabolic Diseases announces the institution of the **Paulescu Award** for innovative basic or clinical research in the field of insulin. The prize, in the amount of US\$ 10.000, will be distributed every 3 years during the IDF Congress, on which occasion the recipient will deliver a plenary Paulescu Award lecture. The first prize will be awarded in August 2003 at the IDF Congress in Paris. Proposals (Justification, CV and major references related to the topic – one page each) should be sent not later than the **end of February 2003** to the Chairman of the Selection Committee:

Prof. Zvi Laron

Schneider, Children's Medical Center of Israel

14 Kaplan Street

I-49202 Petah Tikva

Israel

Tel: +972-3-9253610/1

Fax: +972-3-9222996

E-mail: laronz@clalit.org.il

Position vacant

A post-doc position (Poste vert INSERM) is available at INSERM U568 "Molecular Signaling and Obesity" at the School of Medicine in Nice, France. The Director is Y. Le Marchand-Brustel.

The title of the Project is '**Role of Rab4 and its effectors in insulin-induced glucose transport**'.

The lab is working on the mechanisms involved in insulin-induced glucose transport in normal or pathological situations, focussing on the insulin signaling pathways implicated in the stimulation of glucose transport and in the trafficking of the glucose transporters Glut 4. The candidate (Ph.D.) must be less than 40 years old, not a French citizen, with a solid background in molecular biology and cellular biology. The candidate will be in charge of a project approaching the mechanisms involved in Glut 4 trafficking by the use of transgenic animals. He/She will have to establish the ES cells. In parallel, the candidate will

study the mechanisms involved in insulin-induced glucose transport by cellular approaches.

The position is available from January 2003 for 2 years with a possible extension to 3 years.

Salary will be in the range Euro 2.100-2.900 monthly according to qualifications and experience.

Further enquiries and applications (enclosing a CV and referees) should be sent to:

Dr Mireille Cormont
INSERM U568
Faculté de Médecine
Avenue de Valombrose
F-06107 Nice cedex 02
France
Fax: +33 4 93 37 77 01
Email: cormont@unice.fr